Neuromyelitis Optica Spectrum Disorder: From Basic Research to Clinical Perspectives

Int J Mol Sci. 2022 Jul 18;23(14):7908. doi: 10.3390/ijms23147908.

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disease of the central nervous system characterized by relapses and autoimmunity caused by antibodies against the astrocyte water channel protein aquaporin-4. Over the past decade, there have been significant advances in the biologic knowledge of NMOSD, which resulted in the IDENTIFICATION of variable disease phenotypes, biomarkers, and complex inflammatory cascades involved in disease pathogenesis. Ongoing clinical trials are looking at new treatments targeting NMOSD relapses. This review aims to provide an update on recent studies regarding issues related to NMOSD, including the pathophysiology of the disease, the potential use of serum and cerebrospinal fluid cytokines as disease biomarkers, the clinical utilization of ocular coherence tomography, and the comparison of different animal models of NMOSD.

Keywords: Müller cell; aquaporin-4; astrocyte; complement; microcystic macular degeneration; microglia; myelin oligodendrocyte glycoprotein; neuromyelitis optica spectrum disease; ocular coherence tomography; oligodendrocyte.

Publication types

  • Review

MeSH terms

  • Animals
  • Aquaporin 4
  • Autoantibodies
  • Biomarkers
  • Myelin-Oligodendrocyte Glycoprotein
  • Neuromyelitis Optica*
  • Recurrence

Substances

  • Aquaporin 4
  • Autoantibodies
  • Biomarkers
  • Myelin-Oligodendrocyte Glycoprotein